Managing Director & Partner
Lu Chen is a core member of the Health Care practice area at Boston Consulting Group. She specializes in working with clients in the pharmaceutical industry across segments including innovative pharma, specialty pharma, generics, and biosimilars.
Lu has extensive experience working with clients on CEO transitions, corporate strategy, portfolio strategy, corporate development and M&A (including commercial due diligence), portfolio and pipeline valuation, market entry strategy, go-to-market model, supply chain strategy, large scale transformation, business model innovation, and other areas. She has worked with global pharma and generics clients, as well as Asia-specific companies. Her work has also covered pricing, and PMI.
Before joining BCG, Lu worked as Postdoctoral Fellow at Mayo Clinic and Baylor College of Medicine, focusing on oncology research.
Powerful trends are shaping a promising yet challenging decade for the industry.
Pockets of opportunity await generic-drug companies that are prepared to adopt new strategies.
BCG’s 2019 benchmark study found that companies need to relentlessly manage the elements that demand the greatest spending—internal and contract manufacturing.
Top-line growth is an imperative for medtech and biopharma companies. With so much pressure to contain costs, these companies need to find new ways to thrive and grow.
Biologics representing billions of dollars in sales will lose their marketing exclusivity over the next few years—but the market for biosimilars will grow more slowly than expected.